Clinical Trial Update: Tremelimumab With Chemoembolization or Ablation for Liver Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial exploring tremelimumab combined with chemoembolization or ablation for liver cancers has completed enrollment with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cancer
• Biliary Tract Neoplasms
• Hepatocellular Carcinoma
• Liver Cancer

Drugs mentioned

• Tremelimumab (tremelimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Heptocellular Cancer, Biliary Tract Neoplasms | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-12-10